Table 2 Subgroup analysis results table
Subgroups | Number of studies | CRF Prevalence | 95%CI | I2 | P | |
|---|---|---|---|---|---|---|
Types of cancer | Ovarian Cancer | 9 | 77% | 57–93% | 98.87% | 0.000 |
Cervical Cancer | 8 | 94% | 80–100% | 98.37% | 0.000 | |
Endometrial Cancer | 3 | 90% | 34–100% | - | - | |
Gynecological Cancer | 8 | 93% | 85–99% | 95.15% | 0.000 | |
Scales for CRF | BFI | 6 | 94% | 80–100% | 97.88% | 0.000 |
PFS-R | 5 | 99% | 96–100% | 83.81% | 0.000 | |
PFS | 4 | 91% | 69–100% | 98.27% | 0.000 | |
CFS | 4 | 96% | 84–100% | 95.03% | 0.000 | |
FACIT-F | 3 | 49% | 37–61% | - | - | |
FQ | 1 | 53% | 44–62% | - | - | |
EORTC QLQ-C30 | 1 | 71% | 61–79% | - | - | |
MSAS | 1 | 95% | 91–97% | - | - | |
FAS | 1 | 42% | 38–46% | - | - | |
MFI-20 | 1 | 100% | 92–100% | - | - | |
Developed Degree | Developed Country | 10 | 71% | 57–84% | 98. 04% | 0.000 |
Developing Country | 18 | 95% | 90–99% | 97.83% | 0.000 | |
Countries | China | 18 | 95% | 90–99% | 97.28% | 0.000 |
Korea | 3 | 68% | 29–96% | - | - | |
Canada | 2 | 60% | 54–65% | - | - | |
Norway | 1 | 53% | 44–62% | - | - | |
Japan | 1 | 100% | 94–100% | - | - | |
Netherlands | 1 | 42% | 38–46% | - | - | |
Australia | 1 | 57% | 53–61% | - | - | |
French | 1 | 100% | 92–100% | |||